Meeting
2022 ASCO Annual Meeting
Randomized phase 2 study evaluating efficacy and safety of inupadenant in combination with chemotherapy in adults with metastatic non–small cell lung cancer (mNSCLC) who progressed on immunotherapy.
Authors
Mary E.R. O'Brien
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Surrey, United Kingdom
Mary E.R. O'Brien , Parneet K. Cheema , Christian Grohé , Enric Carcereny Costa , Nicolas Girard , Alberto Chiappori , Sally Ross , Maura Rossetti , Frederic Dubois , Joanne J. Lager , Shouryadeep Srivastava , Vamsidhar Velcheti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
EudraCT 2021-005487-22
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9158)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9158
Abstract #
TPS9158
Poster Bd #
133b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force
Poster
2022 ASCO Annual Meeting
A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).
First Author: Michaël Duruisseaux
Poster
2019 ASCO Annual Meeting
ORION: A Phase 2, randomized, multicenter, double-blind study to assess efficacy and safety of durvalumab+olaparib vs durvalumab alone as maintenance therapy in Stage IV non-small cell lung cancer (NSCLC).
First Author: Myung-Ju Ahn
Poster
2014 ASCO Annual Meeting
NEOSCAN: Phase II trial of neoadjuvant chemotherapy for resectable lung cancers with switch to chemo alternative in 18F-FDG PET nonresponders.
First Author: Mark G. Kris